uniQure's AMT-130 Faces Regulatory Uncertainty for Huntington's Disease

uniQure's AMT-130 is an investigational gene therapy for Huntington's disease, a devastating neurodegenerative disorder with limited treatment options. The FDA's feedback indicates that the agency now believes that data from Phase I/II studies of AMT-130 in comparison to an external control may not be adequate to provide the primary evidence in support of a BLA submission. This is a key shift from prior communications with the FDA.

The company expects to receive final minutes within 30 days of the meeting and plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of AMT-130. In parallel, uniQure intends to progress discussions with other regulatory agencies, including in the European Union and United Kingdom.

While the pace of HD research appears to be accelerating, researchers are dedicated to relaying an accurate message to the community and the field is appropriately mindful of safety signals, false leads, and the need for robust data.

AMT-130 is uniQure's investigational gene therapy for Huntington's Disease.

The FDA indicated that Phase I/II data versus an external control may no longer suffice for a BLA, creating uncertainty for AMT-130's U.S. approval timeline.

AMT-130 holds Breakthrough Therapy (April 2025) and RMAT (May 2024) designations.

uniQure plans urgent FDA engagement and parallel EU/UK regulatory discussions.

The regulatory path for uniQure's AMT-130 is now less clear, highlighting the challenges in developing treatments for complex diseases like Huntington's. Despite the setback, uniQure remains committed to working with regulatory agencies to find a path forward. The Huntington's Disease Clinical Research Congress 2025 emphasized collaboration and data sharing, crucial for continued progress.

Do you think AMT-130 will eventually gain approval? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!